[76Br]BMK-152, a nonpeptide analogue, with high affinity and low nonspecific binding for the corticotropin-releasing factor type 1 receptor

Synapse

Volumn 65, Issue 9, 2011, Pages 910-918

  Jagoda, Elaine M ^a   Lang, Lixin ^a   Mccullough, Karen ^b   Contoreggi, Carlo ^b   Kim, B Moon ^c   Ma, Ying ^a   Rice, Kenner C ^d   Szajek, Lawrence P ^e   Eckelman, William C ^f   Kiesewetter, Dale O ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c Seoul National University   (South Korea)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Molecular Tracer LLC   (United States)

Author keywords

Br 76 BMK; Corticotropin releasing factor type 1 receptors; CRF1 receptor; PET

Indexed keywords

[8 (4 BROMO 2,6 DIMETHOXYPHENYL) 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZIN 4 YL] N,N BIS(2 METHOXYETHYL)AMINE; BROMINE 76; CONTRAST MEDIUM; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; EXPERIMENTAL MONKEY; FRONTAL CORTEX; IN VITRO STUDY; ISOTOPE LABELING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY;

ANIMALS; AUTORADIOGRAPHY; BARIUM RADIOISOTOPES; BINDING SITES; BINDING, COMPETITIVE; BRAIN; LIGANDS; MACACA MULATTA; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PROTEIN BINDING; PYRIMIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TRIAZINES;

EID: 79959985843     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20919     Document Type: Article

References (50)

1. Altholtz LY, Fowler KA, Badura LL, Kovacs MS. 2006. Comparison of the stress response in rats to repeated isoflurane or CO2:O2 anesthesia used for restraint during serial blood collection via the jugular vein. J Am Assoc Lab Anim Sci 45: 17-22.
2. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. 1999. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160: 1-12.
3. Berger H, Heinrich N, Wietfeld D, Bienert M, Beyermann M. 2006. Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain. Br J Pharmacol 149: 942-947.
4. Beyermann M, Heinrich N, Fechner K, Furkert J, Zhang W, Kraetke O, Bienert M, Berger H. 2007. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain. Br J Pharmacol 151: 851-859.
5. De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, Kuhar MJ. 1985. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: An autoradiographic study. J Neurosci 5: 3189-3203.
6. De Souza EB, Kuhar MJ. 1986a. Corticotropin-releasing factor receptors in the pituitary gland and central nervous system: Methods and overview. Methods Enzymol 124: 560-590.
7. De Souza EB, Kuhar MJ. 1986b. Corticotropin-releasing factor receptors: Autoradiographic identification. Res Publ Assoc Res Nerv Ment Dis 64: 179-198.
8. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF, Licinio J, Wong ML, Chrousos GP, Webster E, Gold PW. 1999. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140: 79-86.
9. Ducottet C, Griebel G, Belzung C. 2003. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatry 27: 625-631.
10. Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. 2004. PET Studies on P-glycoprotein function in the blood-brain barrier: How it affects uptake and binding of drugs within the CNS. Curr Pharm Des 10: 1493-1503.
11. Grigoriadis DE, Dent GW, Turner JG, Uno H, Shelton SE, De Souza EB, Kalin NH. 1995. Corticotropin-releasing factor (CRF) receptors in infant rhesus monkey brain and pituitary gland: Biochemical characterization and autoradiographic localization. Dev Neurosci 17: 357-367.
12. Grigoriadis DE, Hoare SR, Lechner SM, Slee DH, Williams JA. 2009. Drugability of extracellular targets: Discovery of small molecule drugs targeting allosteric, functional, and subunit-selective sites on GPCRs and ion channels. Neuropsychopharmacology 34: 106-125.
13. Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB. 1996a. 125I-Tyro-sauvagine: A novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors. Mol Pharmacol 50: 679-686.
14. Grigoriadis DE, Lovenberg TW, Chalmers DT, Liaw C, De Souze EB. 1996b. Characterization of corticotropin-releasing factor receptor subtypes. Ann NY Acad Sci 780: 60-80.
15. Grigoriadis DE, Struble RG, Price DL, De Souza EB. 1989. Normal pattern of labeling of cerebral cortical corticotropin-releasing factor (CRF) receptors in Alzheimer's disease: Evidence from chemical cross-linking studies. Neuropharmacology 28: 761-764.
16. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM. 2006. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: New molecular targets. CNS Neurol Disord Drug Targets 5: 453-479.
17. Hauger RL, Risbrough V, Oakley RH, Olivares-Reyes JA, Dautzenberg FM. 2009. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann NY Acad Sci 1179: 120-143.
18. He L, Gilligan PJ, Zaczek R, Fitzgerald LW, McElroy J, Shen HS, Saye JA, Kalin NH, Shelton S, Christ D, Trainor G, Hartig P. 2000. 4-(1, 3-Dimethoxyprop-2-ylamino)-2, 7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1, 5-a]-1, 3, 5-triazine: A potent, orally bioavailable CRF(1) receptor antagonist. J Med Chem 43: 449-456.
19. Hoare SR. 2005. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 10: 417-427.
20. Hoare SR, Sullivan SK, Ling N, Crowe PD, Grigoriadis DE. 2003a. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol Pharmacol 63: 751-765.
21. Hoare SR, Sullivan SK, Pahuja A, Ling N, Crowe PD, Grigoriadis DE. 2003b. Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: Detection, and pharmacological evaluation by peptide ligands. Peptides 24: 1881-1897.
22. Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE. 2004. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: Regulation by G-protein and nonpeptide antagonists. Biochemistry 43: 3996-4011.
23. Hotchkiss CE, Brommage R, Du M, Jerome CP. 1998. The anesthetic isoflurane decreases ionized calcium and increases parathyroid hormone and osteocalcin in cynomolgus monkeys. Bone 23: 479-484.
24. Hsin LW, Tian X, Webster EL, Coop A, Caldwell TM, Jacobson AE, Chrousos GP, Gold PW, Habib KE, Ayala A, Eckelman WC, Contoreggi C, Rice KC. 2002. CRHR1 Receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists. Bioorg Med Chem 10: 175-183.
25. Jagoda E, Contoreggi C, Lee MJ, Kao CH, Szajek LP, Listwak S, Gold P, Chrousos G, Greiner E, Kim BM, Jacobson AE, Rice KC, Eckelman W. 2003. Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: Synthesis of [(76)Br]MJL-1-109-2. J Med Chem 46: 3559-3562.
26. Jagoda EM, Vaquero JJ, Seidel J, Green MV, Eckelman WC. 2004. Experiment assessment of mass effects in the rat: Implications for small animal PET imaging. Nucl Med Biol 31: 771-779.
27. Jutkiewicz EM, Wood SK, Houshyar H, Hsin LW, Rice KC, Woods JH. 2005. The effects of CRF antagonists, antalarmin. CP154, 526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berl) 180: 215-223.
28. Kiesewetter DO, Jagoda EM, Kao CH, Ma Y, Ravasi L, Shimoji K, Szajek LP, Eckelman WC. 2003. Fluoro-, bromo-, and iodopaclitaxel derivatives: Synthesis and biological evaluation. Nucl Med Biol 30: 11-24.
29. Kolber BJ, Boyle MP, Wieczorek L, Kelley CL, Onwuzurike CC, Nettles SA, Vogt SK, Muglia LJ. 2010. Transient early-life forebrain corticotropin-releasing hormone elevation causes long-lasting anxiogenic and despair-like changes in mice. J Neurosci 30: 2571-2581.
30. Lang L, Ma Y, Kim BM, Jagoda EM, Rice KC, Szajek LP, Contoreggi C, Gold PW, Chrousos GP, Eckelman WC, Kiesewetter DO. 2009. [Br-76]BMK-I-152, a non-peptide analogue for PET imaging of corticotropin-releasing hormone type 1 receptor (CRHR1). J Labelled Compd Rad 52: 394-400.
31. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T. 1995. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 92: 836-840.
32. Millan MA, Jacobowitz DM, Hauger RL, Catt KJ, Aguilera G. 1986. Distribution of corticotropin-releasing factor receptors in primate brain. Proc Natl Acad Sci USA 83: 1921-1925.
33. Owens MJ, Nemeroff CB. 1991. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43: 425-473.
34. Passchier J, van Waarde A, Doze P, Elsinga PH, Vaalburg W. 2000. Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats. Eur J Pharmacol 407: 273-280.
35. Preckel B, Bolten J. 2005. Pharmacology of modern volatile anaesthetics. Best Pract Res Clin Anaesthesiol 19: 331-348.
36. Primus RJ, Yevich E, Baltazar C, Gallager DW. 1997. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain. Neuropsychopharmacology 17: 308-316.
37. Refojo D, Holsboer F. 2009. CRH signaling. Molecular specificity for drug targeting in the CNS. Ann NY Acad Sci 1179: 106-119.
38. Rominger DH, Rominger CM, Fitzgerald LW, Grzanna R, Largent BL, Zaczek R. 1998. Characterization of [125I]sauvagine binding to CRH2 receptors: Membrane homogenate and autoradiographic studies. J Pharmacol Exp Ther 286: 459-468.
39. Ruggiero DA, Underwood MD, Rice PM, Mann JJ, Arango V. 1999. Corticotropic-releasing hormone and serotonin interact in the human brainstem: Behavioral implications. Neuroscience 91: 1343- 1354.
40. Sanchez MM, Young LJ, Plotsky PM, Insel TR. 1999. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 408: 365-377.
41. Silberman Y, Bajo M, Chappell AM, Christian DT, Cruz M, Diaz MR, Kash T, Lack AK, Messing RO, Siggins GR, Winder D, Roberto M, McCool BA, Weiner JL. 2009. Neurobiological mechanisms contributing to alcohol-stress-anxiety interactions. Alcohol 43: 509-519.
42. Sullivan GM, Parsey RV, Kumar JS, Arango V, Kassir SA, Huang YY, Simpson NR, Van Heertum RL, Mann JJ. 2007. PET Imaging of CRF1 with [11C]R121920 and [11C]DMP696: Is the target of sufficient density? Nucl Med Biol 34: 353-361.
43. Szajek LP, Kao CH, Kiesewetter DO, Sassaman MB, Lang L, Plascjak P, Eckelman WC. 2004. Radiochimica Acta 92: 291-295.
44. Uetsuki N, Segawa H, Mayahara T, Fukuda K. 2005. The role of CRF1 receptors for sympathetic nervous response to laparotomy in anesthetized rats. Brain Res 1044: 107-115.
45. Valdez GR. 2009. CRF receptors as a potential target in the development of novel pharmacotherapies for depression. Curr Pharm Des 15: 1587-1594.
46. Vale W, Spiess J, Rivier C, Rivier J. 1981. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213: 1394-1397.
47. Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP. 1996. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137: 5747-5750.
48. Wong ML, Webster EL, Spokes H, Phu P, Ehrhart-Bornstein M, Bornstein S, Park CS, Rice KC, Chrousos GP, Licinio J, Gold PW. 1999. Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sci 65: PL53-PL58.
49. Zorrilla EP, Koob GF. 2010. Progress in corticotropin-releasing factor-1 antagonist development. Drug Discov Today 15: 371-383.
50. Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A. 2002. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952: 188-199.